PCOS Animal Models: An Approach Induced by Dehydroepiandrosterone

Öz

ABSTRACT Polycystic ovary syndrome (PCOS) is one of the most common metabolic and endocrine diseases in women. Researchers generally use animal models in order to observe mechanisms of PCOS. One of the PCOS animal model is dehydroepiandrosterone (DHEA)-induced PCOS model. In this model human PCOS-like features were observed. In the present study DHEA induced pcos animal models are investigated according to species,age,number of groups, animal weight, DHEA amount applied, solvent,solvent amount, treatment days and injection way. ÖZ Polikistik over sendromu (PCOS), kadınlarda en sık görülen metabolik ve endokrin hastalıklardan biridir. Araştırmacılar, PKOS'un mekanizmalarını gözlemlemek için genellikle hayvan modellerini kullanırlar.PKOS hayvan modellerinden biri dehidroepiandrosteron (DHEA) ile indüklenen PKOS modelidir.Bu modelde insan PKOS benzeri özellikler gözlemlenmiştir. Bu çalışmada DHEA ile indüklenen PKOS hayvan modelleri tür, yaş, grup sayısı, hayvan ağırlığı, uygulanan DHEA miktarı, solvent, solvent miktarı, tedavi günleri ve enjeksiyon şekline göre incelenmiştir.

Anahtar Kelimeler

• dehydroepiandrosterone
• polycystic ovary syndrome
• animal models

Kaynakça

1. REFERENCES 1. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057.
2. 2. Sander VA, Hapon MB, Sícaro L, Lombardi EP, Jahn GA, Motta AB. Alterations of folliculogenesis in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2011;124(1-2):58-64.
3. 3. Carmina E. Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines. Minerva ginecologica. 2004;56(1):1-6.
4. 4. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25.
5. 5. Setji TL, Brown AJ. Polycystic ovary syndrome: update on diagnosis and treatment. Am J Med. 2014;127(10):912-9.
6. 6. Traish AM, Kang HP, Saad F, Guay AT. Dehydroepiandrosterone (DHEA)—a precursor steroid or an active hormone in human physiology (CME). The journal of sexual medicine. 2011;8(11):2960-82.
7. 7. Luchetti CG, Solano ME, Sander V, Arcos ML, Gonzalez C, Di Girolamo G, et al. Effects of dehydroepiandrosterone on ovarian cystogenesis and immune function. J Reprod Immunol. 2004;64(1-2):59-74.
8. 8. Kim E-J, Jang M, Choi JH, Park KS, Cho I-H. An Improved Dehydroepiandrosterone-Induced Rat Model of Polycystic Ovary Syndrome (PCOS): Post-pubertal Improve PCOS's Features. Frontiers in Endocrinology. 2018;9(735).

9. 9. Zhang H, Yi M, Zhang Y, Jin H, Zhang W, Yang J, et al. High-fat diets exaggerate endocrine and metabolic phenotypes in a rat model of DHEA-induced PCOS. Reproduction. 2016;151(4):431-41.
10. 10. Choi JH, Jang M, Kim EJ, Lee MJ, Park KS, Kim SH, et al. Korean Red Ginseng alleviates dehydroepiandrosterone-induced polycystic ovarian syndrome in rats via its antiinflammatory and antioxidant activities. J Ginseng Res. 2020;44(6):790-8.
11. 11. Misugi T, Ozaki K, El Beltagy K, Tokuyama O, Honda K, Ishiko O. Insulin-lowering agents inhibit synthesis of testosterone in ovaries of DHEA-induced PCOS rats. Gynecol Obstet Invest. 2006;61(4):208-15.
12. 12. Shen Q, Bi H, Yu F, Fan L, Zhu M, Jia X, et al. Nontargeted metabolomic analysis of skeletal muscle in a dehydroepiandrosterone-induced mouse model of polycystic ovary syndrome. Mol Reprod Dev. 2019;86(4):370-8.
13. 13. Bakhshalizadeh S, Amidi F, Alleyassin A, Soleimani M, Shirazi R, Shabani Nashtaei M. Modulation of steroidogenesis by vitamin D3 in granulosa cells of the mouse model of polycystic ovarian syndrome. Syst Biol Reprod Med. 2017;63(3):150-61.
14. 14. Singh A, Fernandes JRD, Chhabra G, Krishna A, Banerjee A. Liraglutide modulates adipokine expression during adipogenesis, ameliorating obesity, and polycystic ovary syndrome in mice. Endocrine. 2019;64(2):349-66.
15. 15. Eini F, Novin MG, Joharchi K, Hosseini A, Nazarian H, Piryaei A, et al. Intracytoplasmic oxidative stress reverses epigenetic modifications in polycystic ovary syndrome. Reprod Fertil Dev. 2017;29(12):2313-23.
16. 16. Li SY, Song Z, Song MJ, Qin JW, Zhao ML, Yang ZM. Impaired receptivity and decidualization in DHEA-induced PCOS mice. Sci Rep. 2016;6:38134.
17. 17. Emidio GD, Placidi M, Rea F, Rossi G, Falone S, Cristiano L, et al. Methylglyoxal-Dependent Glycative Stress and Deregulation of SIRT1 Functional Network in the Ovary of PCOS Mice. Cells. 2020;9(1).
18. 18. Wen L, Lin W, Li Q, Chen G, Wen J. Effect of Sleeve Gastrectomy on Kisspeptin Expression in the Hypothalamus of Rats with Polycystic Ovary Syndrome. Obesity (Silver Spring). 2020;28(6):1117-28.
19. 19. Furat Rencber S, Kurnaz Ozbek S, Eraldemır C, Sezer Z, Kum T, Ceylan S, et al. Effect of resveratrol and metformin on ovarian reserve and ultrastructure in PCOS: an experimental study. J Ovarian Res. 2018;11(1):55.
20. 20. Solano ME, Sander VA, Ho H, Motta AB, Arck PC. Systemic inflammation, cellular influx and up-regulation of ovarian VCAM-1 expression in a mouse model of polycystic ovary syndrome (PCOS). J Reprod Immunol. 2011;92(1-2):33-44.
21. 21. Tessaro I, Modina SC, Franciosi F, Sivelli G, Terzaghi L, Lodde V, et al. Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome. J Ovarian Res. 2015;8:64.
22. 22. Zhao H, Zhou D, Chen Y, Liu D, Chu S, Zhang S. Beneficial effects of Heqi san on rat model of polycystic ovary syndrome through the PI3K/AKT pathway. Daru. 2017;25(1):21.
23. 23. Yang YL, Sun LF, Yu Y, Xiao TX, Wang BB, Ren PG, et al. Deficiency of Gpr1 improves steroid hormone abnormality in hyperandrogenized mice. Reprod Biol Endocrinol. 2018;16(1):50.
24. 24. Shi Y, Kong X, Yin H, Zhang W, Wang W. Effect of Hawthorn Leaf Flavonoids in Dehydroepiandrosterone-Induced Polycystic Ovary Syndrome in Rats. Pathobiology. 2019;86(2-3):102-10.
25. 25. Kyei G, Sobhani A, Nekonam S, Shabani M, Ebrahimi F, Qasemi M, et al. Assessing the effect of MitoQ(10) and Vitamin D3 on ovarian oxidative stress, steroidogenesis and histomorphology in DHEA induced PCOS mouse model. Heliyon. 2020;6(7):e04279.
26. 26. Wang W, Zheng J, Cui N, Jiang L, Zhou H, Zhang D, et al. Baicalin ameliorates polycystic ovary syndrome through AMP-activated protein kinase. J Ovarian Res. 2019;12(1):109.
27. 27. Kabel AM, Ashour AM, Omar MS, Estfanous RS. Effect of fish oil and telmisartan on dehydroepiandrosterone-induced polycystic ovarian syndrome in rats: The role of oxidative stress, transforming growth factor beta-1, and nuclear factor kappa B. Food Sci Nutr. 2020;8(9):5149-59.
28. 28. Rababa'h AM, Matani BR, Ababneh MA. The ameliorative effects of marjoram in dehydroepiandrosterone induced polycystic ovary syndrome in rats. Life Sci. 2020;261:118353.
29. 29. Roy S, Mahesh VB, Greenblatt RB. Effect of dehydroepiandrosterone and delta4-androstenedione on the reproductive organs of female rats: production of cystic changes in the ovary. Nature. 1962;196:42-3.
30. 30. Ward RC, Costoff A, Mahesh VB. The induction of polycystic ovaries in mature cycling rats by the administration of dehydroepiandrosterone (DHA). Biol Reprod. 1978;18(4):614-23. 31. Abramovich D, Irusta G, Bas D, Cataldi NI, Parborell F, Tesone M. Angiopoietins/TIE2 System and VEGF Are Involved in Ovarian Function in a DHEA Rat Model of Polycystic Ovary Syndrome. Endocrinology. 2012;153(7):3446-56.
31. 32. Wang D, Wang W, Liang Q, He X, Xia Y, Shen S, et al. DHEA-induced ovarian hyperfibrosis is mediated by TGF-β signaling pathway. J Ovarian Res. 2018;11(1):6.
32. 33. Zhang X, Zhang C, Shen S, Xia Y, Yi L, Gao Q, et al. Dehydroepiandrosterone induces ovarian and uterine hyperfibrosis in female rats. Hum Reprod. 2013;28(11):3074-85.
33. 34. Wu G, Hu X, Ding J, Yang J. Abnormal expression of HSP70 may contribute to PCOS pathology. J Ovarian Res. 2019;12(1):74.
34. 35. Zhai J, Li S, Hu M, Di F, Liu J, Du Y. Decreased brain and muscle ARNT-like protein 1 expression mediated the contribution of hyperandrogenism to insulin resistance in polycystic ovary syndrome. Reprod Biol Endocrinol. 2020;18(1):32.
35. 36. Olaniyan OT, Femi A, Iliya G, Ayobami D, Godam E, Olugbenga E, et al. Vitamin C suppresses ovarian pathophysiology in experimental polycystic ovarian syndrome. Pathophysiology. 2019;26(3-4):331-41.
36. 37. Sun L, Ji C, Jin L, Bi Y, Feng W, Li P, et al. Effects of Exenatide on Metabolic Changes, Sexual Hormones, Inflammatory Cytokines, Adipokines, and Weight Change in a DHEA-Treated Rat Model. Reprod Sci. 2016;23(9):1242-9.
37. 38. Zhou DN, Li SJ, Ding JL, Yin TL, Yang J, Ye H. MIF May Participate in Pathogenesis of Polycystic Ovary Syndrome in Rats through MAPK Signalling Pathway. Curr Med Sci. 2018;38(5):853-60.
38. 39. Peng Y, Yang X, Luo X, Liu C, Cao X, Wang H, et al. Novel mechanisms underlying anti-polycystic ovary like syndrome effects of electroacupuncture in rats: suppressing SREBP1 to mitigate insulin resistance, mitochondrial dysfunction and oxidative stress. Biol Res. 2020;53(1):50.
39. 40. Ubba V, Soni UK, Chadchan S, Maurya VK, Kumar V, Maurya R, et al. RHOG-DOCK1-RAC1 Signaling Axis Is Perturbed in DHEA-Induced Polycystic Ovary in Rat Model. Reprod Sci. 2017;24(5):738-52.
40. 41. Yaba A, Demir N. The mechanism of mTOR (mammalian target of rapamycin) in a mouse model of polycystic ovary syndrome (PCOS). J Ovarian Res. 2012;5(1):38.
41. 42. Huang Y, Yu Y, Gao J, Li R, Zhang C, Zhao H, et al. Impaired oocyte quality induced by dehydroepiandrosterone is partially rescued by metformin treatment. PLoS One. 2015;10(3):e0122370.
42. 43. Dou L, Zheng Y, Li L, Gui X, Chen Y, Yu M, et al. The effect of cinnamon on polycystic ovary syndrome in a mouse model. Reprod Biol Endocrinol. 2018;16(1):99.
43. 44. Kuyucu Y, Sencar L, Tap Ö, Mete U. Investigation of the effects of vitamin D treatment on the ovarian AMH receptors in a polycystic ovary syndrome experimental model: an ultrastructural and immunohistochemical study. Reprod Biol. 2020;20(1):25-32.
44. 45. Anderson E, Lee MT, Lee GY. Cystogenesis of the ovarian antral follicle of the rat: ultrastructural changes and hormonal profile following the administration of dehydroepiandrosterone. Anat Rec. 1992;234(3):359-82.
45. 46. Honnma H, Endo T, Henmi H, Nagasawa K, Baba T, Yamazaki K, et al. Altered expression of Fas/Fas ligand/caspase 8 and membrane type 1-matrix metalloproteinase in atretic follicles within dehydroepiandrosterone-induced polycystic ovaries in rats. Apoptosis. 2006;11(9):1525-33.
46. 47. Seow KM, Ting CH, Huang SW, Ho LT, Juan CC. The use of dehydroepiandrosterone-treated rats is not a good animal model for the study of metabolic abnormalities in polycystic ovary syndrome. Taiwan J Obstet Gynecol. 2018;57(5):696-704.
47. 48. Tao X, Chen L, Cai L, Ge S, Deng X. Regulatory effects of the AMPKα-SIRT1 molecular pathway on insulin resistance in PCOS mice: An in vitro and in vivo study. Biochem Biophys Res Commun. 2017;494(3-4):615-20.
48. 49. Hoseinpour MJ, Ghanbari A, Azad N, Zare A, Abdi S, Sajadi E, et al. Ulmus minor bark hydro-alcoholic extract ameliorates histological parameters and testosterone level in an experimental model of PCOS rats. Endocr Regul. 2019;53(3):146-53.
49. 50. Qi X, Zhang B, Zhao Y, Li R, Chang HM, Pang Y, et al. Hyperhomocysteinemia Promotes Insulin Resistance and Adipose Tissue Inflammation in PCOS Mice Through Modulating M2 Macrophage Polarization via Estrogen Suppression. Endocrinology. 2017;158(5):1181-93.
50. 51. Tao X, Zhang X, Ge SQ, Zhang EH, Zhang B. Expression of SIRT1 in the ovaries of rats with polycystic ovary syndrome before and after therapeutic intervention with exenatide. Int J Clin Exp Pathol. 2015;8(7):8276-83.
51. 52. Miao ZL, Guo L, Wang YX, Cui R, Yang N, Huang MQ, et al. The intervention effect of Rosiglitozone in ovarian fibrosis of PCOS rats. Biomed Environ Sci. 2012;25(1):46-52.
52. 53. Jiang YC, Ma JX. The role of MiR-324-3p in polycystic ovary syndrome (PCOS) via targeting WNT2B. Eur Rev Med Pharmacol Sci. 2018;22(11):3286-93.
53. 54. Xue J, Li X, Liu P, Li K, Sha L, Yang X, et al. Inulin and metformin ameliorate polycystic ovary syndrome via anti-inflammation and modulating gut microbiota in mice. Endocr J. 2019;66(10):859-70.